Strong Buy · 95/100Aug 5, 11:46 PM EDT
Moderna's mRNA Flu Shot Wins FDA Approval, Marking Historic First
MRNA
Moderna (MRNA) received FDA approval for its mRNA flu vaccine, mFLUSIVA (mRNA-1010), in adults aged 50-64, with accelerated approval for those 65 and older. This is the first mRNA-based flu vaccine approved, potentially opening a new market and validating the…
- ▹First-ever mRNA flu vaccine approved by FDA, with full approval in one age group and accelerated approval in another, indicating strong regulatory support.
- ▹Platform technology validated with multiple mRNA assets, recent approvals, and potential for rapid adaptation to new strains, enhancing commercial prospects.
Watchlist · 72/100Aug 5, 12:41 PM EDT
Recursion Sets $375M 2026 Cash OpEx Target, Moves First Genentech Neuroscience Program Forward
RXRX
Recursion Pharmaceuticals (RXRX) provided 2026 cash operating expense guidance of $375 million during its Q2 earnings call, signaling disciplined spending as it scales operations. The company is also advancing its first neuroscience target from its collaborati…
- ▹Platform company with differentiated AI-driven drug discovery, partnered with Genentech (Roche) for neuroscience targets, indicating validation and potential milestone payments.
- ▹Cash OpEx guidance of $375M for 2026 suggests disciplined spending, but still pre-commercial with no approved products, capping commercial score.
Watchlist · 70/100Aug 6, 12:31 AM EDT
Sarepta Narrows 2026 Revenue Outlook to $1.2B-$1.3B, Delays Key Gene Therapy Data
SRPT
Sarepta Therapeutics (SRPT) narrowed its 2026 net product revenue guidance to $1.2-$1.3 billion, with the midpoint as the reference, according to CEO Michael. The company also announced that 12-week data from its Cohort 8 study will now be released in Q1 2027,…
- ▹Strong commercial growth with raised guidance for 2026 net product revenue, indicating robust demand for Elevidys.
- ▹Cohort 8 data delay to Q1 2027 introduces uncertainty, but no regulatory negatives; platform and pipeline provide multiple shots on goal.
Watchlist · 70/100Aug 5, 9:31 PM EDT
Caris Life Sciences Projects 2026 Revenue of $1.03B-$1.04B, Eyes $3B Run Rate as Detect Capacity Expands
CAI
Caris Life Sciences (CAI) reported record clinical volume in Q2 2026, driven by investments in its commercial engine. Management forecasts 2026 revenue of $1.03B-$1.04B, with plans to scale Detect capacity toward a $3B run rate, signaling strong growth potenti…
- ▹Record clinical volume and revenue growth indicate strong commercial traction.
- ▹Scaling capacity toward $3B run rate suggests manufacturing and tech investments are paying off.
Watchlist · 70/100Aug 5, 3:41 PM EDT
Kymera Projects Atopic Dermatitis Readout by Late 2026, Cash Reserves Through 2029
KYMR
Kymera Therapeutics (KYMR) provided an update during its Q2 2026 earnings call, reiterating plans to release data for its lead atopic dermatitis candidate KT-621 by the end of 2026. The company also confirmed its cash runway extends into 2029, providing a soli…
- ▹KT-621 is a differentiated oral STAT6 degrader with potential in atopic dermatitis, targeting a large market; cash runway into 2029 reduces near-term dilution risk.
- ▹Single-asset focus and lack of regulatory clarity cap upside; data expected end-2026 is a key catalyst.
Watchlist · 65/100Aug 5, 7:33 PM EDT
ADMA Reaffirms 2026 Revenue Target of $530M-$560M, Plans $200M+ Buyback
ADMA
ADMA Biologics (ADMA) reiterated its 2026 revenue guidance of $530M-$560M and announced plans for over $200M in share repurchases. Management highlighted accelerating demand for its higher-margin immunoglobulin product ASCENIV, with June showing the strongest…
- ▹Commercialized product with strong revenue guidance and buyback program, but single-asset focus and no major regulatory catalysts.
- ▹Manufacturing in US/EU with commercial scale, but lacks platform diversification and recent BD/M&A.
Watchlist · 65/100Aug 5, 12:31 PM EDT
United Therapeutics Guides for 2027 FDA Decisions on Ralinepag and Tyvaso IPF, Keeps 2026 Revenue Forecast Steady
UTHR
United Therapeutics (UTHR) announced in its Q2 2026 earnings call that it expects potential FDA approvals for ralinepag and Tyvaso for IPF in 2027, while reaffirming its 2026 revenue guidance. The company highlighted recent regulatory submissions, including th…
- ▹Multiple regulatory submissions (sNDA for Tyvaso, NDA for ralinepag) with potential 2027 approvals, but no accelerated path or breakthrough designation mentioned.
- ▹Strong commercial portfolio with Tyvaso already marketed and growing, but pipeline assets are single-asset with no platform differentiation.
Neutral · 62/100Aug 5, 11:41 PM EDT
Mirum Raises 2026 Sales Outlook to $680M-$700M; PSC Filing Delayed to First Half
MIRM
Mirum Pharmaceuticals (MIRM) boosted its full-year 2026 net product sales guidance to $680M-$700M after Q2 sales hit $176M. The company also shifted its New Drug Application for a PSC treatment to the first half of next year, a key regulatory milestone for inv…
- ▹Commercial products growing with raised guidance, but PSC NDA delay to 1H next year adds regulatory uncertainty.
- ▹Single-asset focus with limited pipeline diversity caps technology score.
Neutral · 62/100Aug 5, 10:01 PM EDT
Arcutis Boosts 2026 Revenue Outlook to $525M-$540M on ZORYVE Momentum and Telehealth Expansion
ARQT
Arcutis Biotherapeutics (ARQT) raised its 2026 net revenue guidance to $525M-$540M, driven by expanding demand for its topical ZORYVE and new telehealth initiatives. The upward revision signals strong commercial execution and could bolster investor confidence…
- ▹ZORYVE commercial momentum with raised guidance and telehealth expansion
- ▹Single-asset focus and lack of platform differentiation cap upside
Neutral · 62/100Aug 5, 2:31 PM EDT
UroGen's ZUSDURI Surges 73% Sequentially; 2026 Opex Guidance Set at $260M-$270M
URGN
UroGen Pharma reported Q2 2026 net product revenue of $50.4 million for ZUSDURI, a 73% increase quarter-over-quarter, driven by expanding adoption in hospital and community settings. The company guided 2026 operating expenses to $260M-$270M, signaling continue…
- ▹ZUSDURI revenue growing 73% q/q indicates strong commercial traction, but company is still pre-profit with high opex guidance.
- ▹Single-asset focus and lack of platform diversification limit upside, though no regulatory red flags.
Neutral · 62/100Aug 5, 12:03 PM EDT
BioCryst Sets 2026 Revenue Target of $690M-$715M, Operating Costs Guided at $420M-$440M
BCRX
BioCryst Pharmaceuticals (BCRX) provided 2026 total revenue guidance of $690M-$715M, with operating costs expected between $420M-$440M. The company highlighted successful integration of Astria Therapeutics and increased cash generation from growing revenue, si…
- ▹Revenue guidance indicates commercial growth, but no major regulatory catalysts.
- ▹Integration of Astria adds pipeline depth, but single-asset focus and dilution risk cap upside.
Neutral · 59/100Aug 6, 12:10 AM EDT
GRAIL Targets FDA Advisory Panel This Fall, Eyes Approval by Early 2027
GRAL
GRAIL (GRAL) expects an FDA advisory committee meeting in the fall and projects potential approval for its Galleri blood test in the first part of 2027. The company highlighted recent data from PATHFINDER 2 and NHS-Galleri studies, which are key to regulatory…
- ▹FDA advisory committee expected in fall, potential approval in 2027, but no accelerated path or surrogate endpoint mentioned.
- ▹Galleri is a differentiated multi-cancer screening test with strong data from PATHFINDER 2 and NHS-Galleri, but single-asset platform with no recent BD/M&A.
Neutral · 59/100Aug 5, 8:20 PM EDT
Exelixis Trims 2026 Revenue Outlook by $50M, Unveils CRC Launch Strategy for Zanza
EXEL
Exelixis (EXEL) lowered its 2026 revenue guidance midpoint by $50 million during its Q2 earnings call, while outlining launch plans for zanza in colorectal cancer (CRC). The guidance cut may raise concerns, but the CRC launch strategy signals growth potential,…
- ▹Zanza CRC launch plans provide near-term catalyst, but 2026 revenue guidance midpoint lowered by $50M signals demand uncertainty.
- ▹Exelixis has a commercialized product (cabozantinib) and pipeline, but single-asset focus and guidance cut cap upside.
Neutral · 57/100Aug 5, 11:41 PM EDT
Arcus Biosciences Sees $5B-$10B Potential for Casdatifan, PEAK-1 Enrollment Target Set for End of 2026
RCUS
Arcus Biosciences (RCUS) highlighted during its Q2 2026 earnings call that its lead candidate, casdatifan, could generate $5B-$10B in revenue, underscoring its commercial potential. The company aims to complete enrollment for the PEAK-1 trial by the end of 202…
- ▹Casdatifan is a promising HIF-2a inhibitor with potential in renal cell carcinoma, but it's a single-asset focus for Arcus, limiting platform value.
- ▹PEAK-1 enrollment target and PEAK-20 start are positive catalysts, but commercial potential is speculative and manufacturing details are unclear.
Neutral · 57/100Aug 5, 11:30 PM EDT
MannKind Projects $110M-$120M in 2026 Furoscix Sales as ReadyFlow Launch Approaches
MNKD
MannKind (MNKD) guided to $110M-$120M in 2026 revenue for Furoscix, with the ReadyFlow device shipping within weeks. The company's 2026 catalysts include Afrezza pediatric approval, Furoscix ReadyFlow launch, and Phase Ib data for nintedanib DPI, which are key…
- ▹Furoscix revenue target and ReadyFlow launch are positive commercial catalysts, but Afrezza pediatrics approval and Phase Ib readout are pending regulatory/clinical events.
- ▹MannKind has a differentiated inhaled delivery platform, but reliance on single-asset Afrezza and dilution risk from ongoing capital needs cap upside.
Neutral · 57/100Aug 5, 7:01 PM EDT
Revolution Medicines Raises 2026 OpEx Guidance to $2.1B-$2.2B as Daraxonrasib Launch Nears
RVMDRVMDW
Revolution Medicines (RVMD) updated its 2026 GAAP operating expense guidance to $2.1B-$2.2B, reflecting increased investment ahead of a potential daraxonrasib launch. Management highlighted strong progress, including compelling RASolute 302 results and rapid e…
- ▹RASolute 302 results and FDA-cleared expanded access program support regulatory progress, but no approval yet.
- ▹High operating expenses ($2.1B-$2.2B) raise dilution risk and runway concerns, capping narrative score.
Neutral · 57/100Aug 5, 3:34 PM EDT
COMPASS Pathways Eyes H1 2027 COMP360 Launch, Targets Q4 NDA Submission for TRD
CMPS
COMPASS Pathways (CMPS) reported highly statistically significant Phase III primary endpoint readouts for COMP360 in treatment-resistant depression (TRD), with durability demonstrated through six months. The company plans to complete its NDA submission in Q4 a…
- ▹Positive Phase III data and NDA filing planned for Q4, but regulatory path for psychedelics is novel and uncertain.
- ▹Single-asset company with no commercial product yet; launch not until H1 2027, limiting near-term upside.
Neutral · 55/100Aug 6, 4:20 AM EDT
Vir Biotechnology Sets ECLIPSE 1 Data Release for Q4 2026, Extends Cash Runway to 2028
VIR
Vir Biotechnology announced that top-line results from its ECLIPSE 1 study are expected in Q4 2026, following completion of enrollment across all three registrational ECLIPSE trials for hepatitis delta. The company also projects its cash runway to extend into…
- ▹Multiple registrational trials for hepatitis delta completed enrollment, with top-line data expected in Q4 2026, indicating potential regulatory progress.
- ▹Cash runway into 2H 2028 reduces near-term dilution risk, but single-asset focus and lack of commercial revenue cap upside.
High Risk · 49/100Aug 5, 10:41 PM EDT
Akebia Sets Vafseo Pricing Strategy Post-2026 TDAPA; VOICE Trial Shows Favorable Odds
AKBA
Akebia Therapeutics (AKBA) announced plans to reset Vafseo's price after the Dec. 31, 2026 TDAPA period, as the VOICE trial reported win odds of 1.16. This strategic pricing move aims to solidify Vafseo's position in the CKD anemia market, potentially impactin…
- ▹Vafseo is commercialized but faces pricing pressure and TDAPA transition risk; VOICE trial win odds modest (1.16).
- ▹Single-asset focus with limited pipeline diversity and no recent BD/M&A; manufacturing unknown defaults to 7.
High Risk · 37/100Aug 5, 9:00 AM EDT
BiomX Bolsters Drone Testing Portfolio with Strategic Stake in Motomea
PHGE
BiomX (PHGE) has acquired a 10% stake in Motomea, gaining exclusive rights to develop and distribute drone testing solutions. The deal, which includes $50K cash and 1.3M restricted shares, positions BiomX to expand its testing capabilities, potentially opening…
- ▹Diversion into drone testing is unrelated to biotech core, raising strategic concerns.
- ▹Small investment with stock dilution, no clear regulatory or commercial catalyst.